Discontinuing GLP‑1 drugs linked to higher heart attack and stroke risk

A large observational study published this week found that the cardiovascular advantages associated with glucagon‑like peptide‑1 (GLP‑1) receptor agonists may diminish rapidly after treatment cessation. Researchers tracked patients who had been prescribed GLP‑1 drugs such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and compared outcomes for those who discontinued therapy with those who remained on the medication over a two‑year follow‑up period. The analysis showed a 22 percent increase in the combined risk of myocardial infarction, stroke and all‑cause mortality among patients who stopped the drugs, relative to continued users.

The findings add nuance to earlier trials that demonstrated a reduction in major adverse cardiovascular events for individuals receiving GLP‑1 agonists, primarily in populations with type 2 diabetes or obesity. While the new data underscore the potential for sustained benefit with ongoing therapy, they also highlight a possible rebound effect when treatment is halted. Clinicians are advised to consider these risk differentials when planning long‑term management strategies for patients using GLP‑1 agents, and further research is anticipated to clarify the mechanisms behind the observed risk escalation.